Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

NCT06913023 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant Recipient

Interventions

DRUG: Semaglutide 3 MG [Rybelsus]
DRUG: Semaglutide 7 MG [Rybelsus]
DRUG: Semaglutide 14 MG [Rybelsus]
DRUG: Placebo Oral Tablet

Sponsor

University Health Network, Toronto